Related Experiment Video
Updated: Jul 4, 2026
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Considerations for the development of therapeutic monoclonal antibodies
Patrick G Swann1, Mate Tolnay, Subramanian Muthukkumar
1Division of Monoclonal Antibodies, Center for Drugs Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. patrick.swann@fda.hhs.gov
Abstract:
An increasing number of Investigational New Drug (IND) applications for therapeutic monoclonal antibodies (mAbs) have been submitted to US FDA over the past several years. Monoclonal antibodies and related products are under development for a wide range of indications. In addition, the diversity of antibody-related products is increasing including IgG2/IgG4 subclasses and engineered Fc regions to enhance or reduce antibody effector functionality. Recent findings highlight the need to more fully characterize these products and their activity. Advances in product characterization tools, immunogenicity assessments, and other bioanalytical assays can be used to better understand product performance and facilitate development.
More Related Videos
10:50Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System
Published on: May 1, 2019
13:14Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
Published on: February 6, 2018
